Cold Chain Optimisation by Rethinking Pharma Logistics

Cold chain optimisation is needed as pharmaceutical supply chains grow more complex, energy-intensive, and exposed to disruption. Cold chain optimisation models also show how better modelling can improve commercial performance, environmental impact, and supply chain resilience. 

Image

Cold Chain Optimisation: Rethinking Pharma Logistics

Temperature-sensitive medicines cannot be treated like other medicinal products. Their quality can depend on maintaining defined conditions across manufacturing, storage, transport, and delivery.

That creates a supply chain with very little room for error.

Refrigeration consumes energy; temperature-controlled packaging adds cost; delays can extend transit times, and equipment failures, extreme weather, traffic disruption, and power instability can increase the risk of temperature excursions.

Pharma is also handling an increasingly valuable portfolio of biologics, vaccines, and other temperature-sensitive therapies.

Pharmatica recently examined this vulnerability in pharmaceutical cold chain risk, highlighting how extreme weather can expose weaknesses in packaging, refrigeration, monitoring, and transport networks.

The challenge is therefore not simply keeping products cold.

It is maintaining product integrity while balancing cost, service, energy use, carbon emissions, and uncertainty.

Optimisation Needs to Look Across the Supply Chain Network

Looking beyond one isolated logistics decision, there are very specific cold chain optimisation models that can support different components of cold chains and there are still large areas where further research is needed. 

This matters because pharma supply chain and manufacturing decisions are interconnected.

Changing a distribution centre can alter transport distances, changing a route can affect delivery time and refrigeration requirements, and increasing inventory can improve availability but also increase storage costs and energy consumption.

A more sophisticated approach considers these relationships together with cold chain optimisation that can support decisions around:

• Network design: Where should storage and distribution capacity sit?
• Routing: Which transport routes balance time, cost, and temperature requirements?
• Inventory: How much product should be positioned at each node?
• Energy: Where can refrigeration demand be reduced?
• Risk: How should uncertainty affect logistics decisions?
• Sustainability: Can emissions be reduced without compromising service?

This multi-dimensional perspective is an important direction for cold chain strategy.

Image

Uncertainty in Cold Chain Optimisation

A cold change optimisation route that looks great on paper may not remain optimal when conditions change.

Demand can fluctuate. Travel times can vary. Energy consumption can change. Weather can disrupt transport. Equipment can fail.

This is why cold chain optimisation models increasingly need to account for uncertainty rather than assuming that logistics conditions remain constant.

Research continues to show that optimisation models that consider demand uncertainty, travel-time reliability, energy-consumption reliability, and carbon emissions make better pharmaceutical distribution decisions. 

Introducing temporary distribution centres alone could reduce transportation costs by 16% while also significantly lowering carbon emissions. 

This demonstrates that resilience and efficiency do not always have to compete.

The right network design can improve both.

Read Maximise Pharma Innovation With Quality-by-Design

Maximise Pharma Innovation With Quality-by-Design

Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.

Sustainability Is Operational in Pharma Manufacturing

Cold chains have an environmental cost because refrigeration requires energy and temperature-controlled distribution can demand specialised infrastructure.

This means that there are potential commercial, environmental, and social benefits that are important outcomes of cold chain optimisation. 

That changes everything. Sustainability cannot sit separately from logistics planning. Transport mode, route selection, facility location, inventory positioning, and refrigeration requirements can all affect emissions.

Other 2025 research supports this integrated approach. A pharmaceutical logistics network study found that redesigning distribution networks and using alternative transport modes could reduce both costs and carbon emissions under a carbon policy scenario. 

For manufacturers facing increasingly demanding sustainability targets, carbon performance is also an important factor for optimisation.

Data Makes Cold Chains More Predictive

Cold chain optimisation also depends on the quality of the information feeding the model.

Temperature sensors, vehicle data, inventory systems, weather information, demand forecasts, and route data can create a much richer picture of cold chain performance.

This creates an opportunity to move from reactive management towards predictive decision-making.

Instead of discovering that a shipment experienced a problem after delivery, teams could identify emerging risks earlier and adjust routing, storage, or distribution decisions.

Machine-learning approaches and AI can also be used for detecting temperature outliers from transport data, using route information to identify potential cold chain failures.

The value is not simply more data. The value of cold chain optimisation comes from turning data into earlier and better operational decisions.

Cold Chain Optimisation Must Protect Product Quality

Operational efficiency cannot come at the expense of pharmaceutical quality.

The U.S. Food and Drug Administration (FDA) GMP guidance states that materials requiring controlled temperature and humidity should be stored under appropriate conditions, with records maintained where those conditions are critical to material characteristics. It also requires transport arrangements that do not adversely affect product quality. 

This makes cold chain optimisation fundamentally different from ordinary logistics optimisation.

The objective is not to minimise cost at any price. It is to find the best achievable balance between quality, service, resilience, cost, and sustainability.

That requires Technical Operations, Quality, Supply Chain, Manufacturing, and logistics teams to work from shared data and shared risk assumptions.

Cold Chain Optimisation as a Strategic Capability

Cold chain optimisation is moving towards increasingly integrated models that consider multiple operational, environmental, and social factors together. 

Cold chain performance should not be measured only by whether a shipment arrived within its required temperature range. We need to understand why the network performs as it does, where its vulnerabilities sit, and which interventions produce the greatest improvement.

That means combining optimisation models with real operational data, scenario planning, and continuous monitoring.

The result could be a cold chain that is not only more efficient, but more resilient to the disruptions that increasingly define global pharmaceutical logistics.

At Pharmatica, we focus on the systems, strategies, and technologies shaping pharmaceutical Technical Operations. Our Insights connect manufacturing, logistics, sustainability, and supply chain innovation to the decisions that can turn operational improvements into measurable impact.

Pharmatica: Insight. Connection. Impact.

Image